YTEN - Yield10 Bioscience Inc. (YTEN) Q4 2023 Earnings Call Transcript
2024-04-01 23:05:25 ET
Yield10 Bioscience, Inc. (YTEN)
Q4 2023 Earnings Conference Call
April 01, 2024, 04:30 PM ET
Company Participants
Lynne Brum - Vice President of Planning and Corporate Communications
Oliver Peoples - President and Chief Executive Officer
Kristi Snell - Vice President, Research and Chief Science Officer
Chuck Haaser - Chief Accounting Officer
Conference Call Participants
Ben Klieve - Lake Street Capital Market
Presentation
Operator
Welcome to the Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call for Yield10 Bioscience. During this call, participants will be in a listen-only-mode. The presenters will address questions from analysts today. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to turn the conference call over to your host, Yield10, Vice President of Planning and Corporate Communications, Lynne Brum.
Lynne Brum
Thank you, Alicia. Good afternoon, everyone. Welcome to the conference call. Joining me on the call today are President and CEO, Dr. Oli Peoples, Vice President of Research and Chief Science Officer, Dr, Kristi Snell and Chief Accounting Officer, Chuck Haaser. Earlier this afternoon, Yield10 issued our fourth quarter and full year 2023 financial results, as well as our 10-K. The press release as well as slides that accompany today's presentation are available on the Investor Relations events section of our website at yield10bio.com.
Let's turn to slide 2. Please note, as part of our discussion today, management will be making forward-looking statements. These statements are not guarantees of future performance and therefore you should not produce undue reliance on them. Investors are also cautioned that statements are not strictly historical, constitute forward-looking statements, and such forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results to differ materially from those anticipated. These risks include risks and uncertainties detailed in Yield10's filings with the SEC. The Company undertakes no obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this conference call.
I'll turn the call over to Oli.
Oliver Peoples
Thanks, Lynne. Good afternoon everyone, and thanks for joining our call. Let's turn to slide 3. We continue to make progress in our plans to commercialize sustainable products using the oilseed Camelina as a platform crop. We're pursuing Camelina seed oil products for two market opportunities and value chains. Each product has its own scale requirements, timeline and value proposition....
Yield10 Bioscience, Inc. (YTEN) Q4 2023 Earnings Call Transcript